Chris Wong: My recent publications on urothelial carcinoma
Chris Wong, Urology Resident at NTEC Surgery, shared on LinkedIn:
“My recent publications on urothelial carcinoma to European Urology Oncology and Annals of Surgical Oncology, thanks to the supervision of Jeremy Teoh!
In this phase I trial conducted in CUHK Medicine PWH, giving HIVEC (hyperthermic) MMC immediately after transurethral resection of bladder tumour was found equally safe compared to conventional cold MMC. 1-year recurrence profile seemed exceptionally good but further investigation is warranted.
In this 500-patient multi-centre cohort on robot assisted cystectomies, the use of neobladder as opposed to ileal conduit was found to be at least comparable in terms of oncological outcomes. Neobladder was also reported as safe without additional complications.”
Source: Chris Wong/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023